Vyome Holdings Inc (HIND)

07:51 AM

Vyome Reports Positive Phase 2 Data for VT-1953 Gel - TipRanks

07:51 AM

06:13 AM

Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953 - TradingView

06:13 AM

Feb 11, 2026

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months - The Joplin Globe

Feb 11, 2026

Feb 02, 2026

Vyome raises $5.29 million to fund phase 3 trial of MFW treatment - Investing.com Nigeria

Feb 02, 2026

Feb 02, 2026

Vyome raises $5.29 million to fund phase 3 trial of MFW treatment By Investing.com - Investing.com South Africa

Feb 02, 2026

Feb 02, 2026

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results - BioSpace

Feb 02, 2026

Feb 02, 2026

Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results - marketscreener.com

Feb 02, 2026

Feb 02, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Feb 02, 2026

Jan 29, 2026

Penny Stocks To Follow Now – January 27th - Defense World

Jan 29, 2026

Jan 28, 2026

Recommendations-Union Budget FY27, Vyome Holdings, Inc. - Medical Buyer

Jan 28, 2026

Jan 28, 2026

Vyome Holdings Highlights VT-1953 Market Potential Analysis - TipRanks

Jan 28, 2026

Jan 28, 2026

Vyome Holdings, Inc Announces Key Findings on VT-1953 - TradingView

Jan 28, 2026

Jan 27, 2026

Vyome Holdings Stock Tumults After Strategic Moves in Europe - timothysykes.com

Jan 27, 2026

Jan 27, 2026

Hindustan Diverges: Financial Snapshot Paints Varied Picture​ - StocksToTrade

Jan 27, 2026

Jan 27, 2026

Vyome Holdings Eyes Growth Amid Market Turbulence - timothysykes.com

Jan 27, 2026

Jan 27, 2026

Vyome stock soars after analyst values lead drug candidate at $1 billion - Investing.com Canada

Jan 27, 2026

Jan 27, 2026

Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study - Business Wire

Jan 27, 2026

Jan 27, 2026

Vyome (NASDAQ:HIND) and Medline (NASDAQ:MDLN) Critical Survey - Defense World

Jan 27, 2026

Jan 24, 2026

“Malignant fungating wounds remain significantly under-recognised and under-treated in India” - BioSpectrum India

Jan 24, 2026

Jan 07, 2026

MarketsMedicine Hat NewsMedicine Hat NewsVyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - FinancialContent

Jan 07, 2026

Jan 06, 2026

Vyome’s LiveChain signs LOI for Humanyze note acquisition - MSN

Jan 06, 2026

Jan 03, 2026

Vyome Holdings, Inc. (HIND) Competitors - Meyka

Jan 03, 2026

Dec 29, 2025

We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate - Yahoo Finance

Dec 29, 2025

Dec 26, 2025

What is the current Price Target and Forecast for Vyome Holdings, Inc. (HIND) - Zacks Investment Research

Dec 26, 2025

Dec 23, 2025

Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition - TipRanks

Dec 23, 2025

Dec 23, 2025

Vyome Holdings Signs Letter of Intent With Remus Capital Series B II - TradingView — Track All Markets

Dec 23, 2025

Dec 23, 2025

Vyome Holdingson Dec 17, Entered Binding L - 富途牛牛

Dec 23, 2025

Dec 22, 2025

Vyome Subsidiary LiveChain Signs LOI to Take Control of Humanyze Assets - citybiz

Dec 22, 2025

Dec 22, 2025

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company - Yahoo Finance

Dec 22, 2025

Dec 18, 2025

Pomichter Stanley D Iii Net Worth (2026) - GuruFocus

Dec 18, 2025

Dec 18, 2025

Mohanjit Jolly Net Worth (2025) - GuruFocus

Dec 18, 2025

Dec 15, 2025

Vyome inches towards US FDA approval to enter $1B worth malignant fungating wound market - BioSpectrum India

Dec 15, 2025

Dec 09, 2025

Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints - MSN

Dec 09, 2025

Dec 09, 2025

Check Out Vyome Holdings Inc (HIND)’s Trade Data Rather Than the Analysts’ Views - setenews.com

Dec 09, 2025

Dec 09, 2025

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval - BioSpace

Dec 09, 2025

Dec 09, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Dec 09, 2025

Dec 08, 2025

Vyome stock soars after malodor treatment shows positive results - Investing.com

Dec 08, 2025

Dec 08, 2025

Vyome stock soars after malodor treatment shows positive results By Investing.com - Investing.com UK

Dec 08, 2025

Dec 08, 2025

Vyome reports positive final Phase 2 results for VT-1953, plans to advance into pivotal study for FDA approval - marketscreener.com

Dec 08, 2025

Dec 05, 2025

HIND Stock Price and Chart — NASDAQ:HIND - TradingView

Dec 05, 2025

Dec 05, 2025

Vyome Holdings (HIND) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 05, 2025

Dec 02, 2025

JOLLY MOHANJIT Insider Trades - Nasdaq

Dec 02, 2025

Dec 01, 2025

Vyome Holdings, Inc. (HIND) Recent Insider Transactions - Yahoo! Finance Canada

Dec 01, 2025

Nov 28, 2025

Vyome Holdings, Inc. (HIND) recent insider transactions - Yahoo Finance UK

Nov 28, 2025

Nov 28, 2025

Vyome Holdings, Inc. (HIND) Profit Margin (Quarterly) - Zacks Investment Research

Nov 28, 2025

Nov 26, 2025

Vyome Holdings files prospectus related to resale of 610,185 shares of common stock by selling stockholders - marketscreener.com

Nov 26, 2025

Nov 26, 2025

Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders - TradingView

Nov 26, 2025

Nov 26, 2025

Vyome Holdings Inc. Reports Post-Merger Financials - MSN

Nov 26, 2025

Nov 25, 2025

Vyome taps Dr. Bardia as senior medical advisor for wound treatment - Investing.com Nigeria

Nov 25, 2025

Nov 25, 2025

Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor - citybiz

Nov 25, 2025

Nov 25, 2025

Vyome taps Dr. Bardia as senior medical advisor for wound treatment By Investing.com - Investing.com South Africa

Nov 25, 2025